Content
Search
Navigation
Sitemap
About us
About us
Who we are
Our model
Data driven investment process
Our purpose, culture and values
Our history
Our people
Our people
Board of directors
Portfolio
Portfolio
Portfolio data
Cell therapy
Overview
Autolus
Achilles Therapeutics
Quell Therapeutics
Resolution Therapeutics
Clade Therapeutics
Gene therapy
Overview
Freeline Therapeutics
AGTC
SwanBio Therapeutics
Purespring Therapeutics
Biologics
Overview
Anaveon
Small molecule
Overview
OMass Therapeutics
Kesmalea Therapeutics
Mosaic Therapeutics
Previous investments
Overview
Gyroscope Therapeutics
Blue Earth
Nightstar
Neogene Therapeutics
14MG
Azeria Therapeutics
Sustainability
Sustainability
Message from Chair, SIML
Our approach to sustainability reporting
Our social impact
Responsible investor and partner
Overview
Responsible investment process
A responsible partner
Sustainability within the Syncona portfolio
Inspiring and empowering our people
Responsible and ethical business
Overview
Environment
Syncona TCFD disclosure
Syncona’s approach to charity
Overview
The Syncona Foundation
Sustainability policies
News and Insights
Investors
Investors
Investment proposition
KPIs
Results and presentations
RNS and inside information
Share price centre
Governance
Overview
Our Committees
How we communicate with our stakeholders
Regulatory publications
Financial calendar
Analysts and advisers
Shareholder information
Overview
Shareholder documents
FAQs
Contact
Portfolio data
Browse all portfolio data news
Search
Latest portfolio data news
Show news from
all companies
all companies
all Cell therapy companies
Autolus
Achilles Therapeutics
all Gene therapy companies
Freeline Therapeutics
all Biologics companies
Anaveon
all Small molecule companies
Clear filters
26.04.23
Autolus Therapeutics Announces Data from AUTO1/22 Trial in Pediatric Acute Lymphoblastic Leukemia in an Oral Presentation at the EBMT 49th Annual Meeting
Operating News
Cell therapy
Autolus
06.12.22
Achilles Therapeutics Presents Encouraging Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma at ESMO IO Congress 2022
Operating News
Cell therapy
Achilles Therapeutics
01.12.22
Achilles Therapeutics to Present Early Proof of Concept of Safety and Clinical Activity of Clonal Neoantigen Reactive T Cells at the ESMO Immuno-Oncology Annual Congress 2022
Cell therapy
Achilles Therapeutics
15.11.22
Freeline Reports Third Quarter 2022 Financial Results and Corporate Update
Operating News
Gene therapy
Freeline Therapeutics
10.11.22
Anaveon presents updated data from the Phase I/II study of ANV419 during the SITC Annual Meeting
Operating News
Biologics
Anaveon
03.11.22
Autolus Therapeutics to Present Three Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2022
Cell therapy
Autolus
Load more
Close menu
About us
About us
Who we are
Our model
Data driven investment process
Our purpose, culture and values
Our history
Our people
Our people
Board of directors
Portfolio
Portfolio
Portfolio data
Cell therapy
Overview
Autolus
Achilles Therapeutics
Quell Therapeutics
Resolution Therapeutics
Clade Therapeutics
Gene therapy
Overview
Freeline Therapeutics
AGTC
SwanBio Therapeutics
Purespring Therapeutics
Biologics
Overview
Anaveon
Small molecule
Overview
OMass Therapeutics
Kesmalea Therapeutics
Mosaic Therapeutics
Previous investments
Overview
Gyroscope Therapeutics
Blue Earth
Nightstar
Neogene Therapeutics
14MG
Azeria Therapeutics
Sustainability
Sustainability
Message from Chair, SIML
Our approach to sustainability reporting
Our social impact
Responsible investor and partner
Overview
Responsible investment process
A responsible partner
Sustainability within the Syncona portfolio
Inspiring and empowering our people
Responsible and ethical business
Overview
Environment
Syncona TCFD disclosure
Syncona’s approach to charity
Overview
The Syncona Foundation
Sustainability policies
News and Insights
Investors
Investors
Investment proposition
KPIs
Results and presentations
RNS and inside information
Share price centre
Governance
Overview
Our Committees
How we communicate with our stakeholders
Regulatory publications
Financial calendar
Analysts and advisers
Shareholder information
Overview
Shareholder documents
FAQs
Contact
Search
Search